Elevation Oncology Inc
Change company Symbol lookup
Select an option...
ELEV Elevation Oncology Inc
CPSI Computer Programs and Systems Inc
TKNO Alpha Teknova Inc
BTM Bitcoin Depot Inc
RC Ready Capital Corp
NEOV NeoVolta Inc
SCHL Scholastic Corp
SIDU Sidus Space Inc
MGY Magnolia Oil & Gas Corp
CWBR CohBar Inc
Go

Health Care : Biotechnology | Small Cap Value

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 (SYSA1801 or CPO102), is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Claudin 18.2 is expressed across several solid tumor types, including many gastrointestinal cancers such as gastric, gastroesophageal junction and pancreatic cancer. Claudin 18.2 is also expressed in ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors. The Company is exploring opportunities through new or existing partnerships and business development opportunities to expand its novel oncology pipeline.

Closing Price: $0.70

Day's Change: -0.0164 (-2.29%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.72

Day's Low: 0.6822

Volume (Light) Volume: 32,471 10-day average volume: 182,845: 32,471

September 05, 2023
7:30 am ET	Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced...(PR Newswire)
August 16, 2023
7:30 am ET	Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021 Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced...(PR Newswire)
August 03, 2023
7:31 am ET	Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements -- Initial Phase 1 SYSA1801 (EO-3021) data presented by partnerCSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2...(PR Newswire)
July 13, 2023
8:01 am ET	Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the...(PR Newswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and